Biosynthetic Cocaine? PharmaDrug Files Patent For Novel Manufacturing Method

FULL DISCLOSURE: This content is sponsored by PharmaDrug Inc.

PharmaDrug’s (CSE: PHRX) subsidiary SecureDose has finally revealed its first biosynthetic formulation: pharmaceutical grade cocaine.

SecureDose is reportedly initiating work on a novel manufacturing method for the commercial-scale production of cocaine, which will be produced to support safe supply programs.

PTX Metals Inc. — sponsored Sponsored · PTX Metals Inc.

“We have seen the proliferation of safe supply programs in both Canada and around the world. While opioid addiction is a serious problem, there exists a supply chain that provides both natural and synthetic opioid products for those programs,” commented Robert Steen, CEO of PharmaDrug.

“Cocaine, however, is the illegal drug that causes the most cost and harm to society barring opioids according to the Canadian Centre for Substance Use and Addiction, causing $4.2 Billion1 in harm in Canada annually – but there is no supply chain to alleviate these harms.”

READ: PharmaDrug Names Dr David Kideckel As Chairman, While SecureDose Finalizes Formulation

A patent has been filed for a method of development that uses biosynthetic chemistry that the company believes will allow for the use of GMP manufacturing in the production of pharmaceutical grade cocaine. The intent is that the resulting product will be a reliable, regulated, clinically manufactured product that is suitable for use in safe supply programs.

A lab has already been identified by the company that will be used for the development of the novel process. An accelerated development timeframe is being pursued by the lab, with the manufacturing process to target the cost effective and efficient production of cocaine.

PharmaDrug last traded at $0.06 on the CSE.


FULL DISCLOSURE: PharmaDrug is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of PharmaDrug. The author has been compensated to cover PharmaDrug on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Is Cocaine Turning The Tide Towards Legalization?

Switzerland is currently reevaluating its stance on drug policy as reports emerge of a groundbreaking...
Wednesday, March 20, 2024, 10:40:00 AM

PharmaDrug JV Submits Application For Phase 1 Clinical Trials In Australia

PharmaDrug Inc (CSE: DRUG) has seen one of its joint ventures advance to the clinical...
Wednesday, May 15, 2024, 09:17:48 AM

Pharmadrug Completes Super Smart Acquisition, Issues 64.4 Million Free Trading Shares

Pharmadrug Inc (CSE: BUZZ) announced this morning that it has completed its acquisition of Interrobang...

Monday, June 15, 2020, 02:44:06 PM

PharmaDrug’s Sairiyo To Begin Manufacturing PD-001 For Clinical Trials In Q2

PharmaDrug (CSE: PHRX) has seen its joint venture with PharmaTher Holdings (CSE: PHRM) begin to...
Wednesday, February 14, 2024, 09:46:59 AM

PharmaDrug: Cepharanthine Identified For Potential To Bind To Monkeypox Proteins In Independent Screening

PharmaDrug (CSE: PHRX) is reporting this morning that cepharanthine, of which their subsidiary has developed...
Wednesday, August 21, 2024, 10:26:03 AM